Sign in
Enrolling by invitationNo phase

Weight Loss and Safety of Semaglutide in Korean Adults Living With Obesity

Follows adults in Korea with obesity who are prescribed semaglutide by their doctors.

Key facts

Who runs it
Novo Nordisk A/S
Where
Busan, Daegu, Daejeon, Goyang-si, Gwangmyeong-si, Gyeonggi-do, Seongnam-si, Seongnam-si, Gyeonggi-do, Seoul, Suwon, Uijeongbu-si, Uijeongbu-si, Gyeonggi-do, Yangsan, and Yongin-si, South KoreaSee the 18 sites
Trial code
Registry title
WEgovy Real World Assessment of Weight Loss in Korea
Status
Enrolling by invitation
People taking part
500 people, planned
Started
10 Nov 2025
Expected to end
31 Oct 2027
Type of study
Observational
Treatments tested
  • Semaglutide
Record updated
30 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity in Korea who are starting Wegovy (semaglutide) for the first time as part of their normal care. It follows weight change and safety for about 52 weeks.

Age
19 years or older
Sex
Men and women can join.
Disease stage
Obesity.
Earlier treatment
Must be starting Wegovy (semaglutide) for the first time, as the label says. The decision to treat was made by the patient and doctor before and apart from joining the study. Must not have taken part before in a clinical study with Wegovy (semaglutide).

Main reasons for not taking part

  • Took part before in a clinical study that included Wegovy (semaglutide)
  • Pregnant, breast-feeding, or planning to become pregnant
  • Able to have children but not using adequate contraception
  • Mental incapacity, unwillingness or language barriers that stop understanding or co-operation

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
  • The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study
  • Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label
  • Male or female, aged ≥ 19 years at the time of signing the informed consent

Who cannot take part

  • Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study
  • Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice)
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation

Where in South Korea

  • Dong-A University HospitalBusan, South KoreaEnrolling by invitation
  • Inje University Haeundae Paik HospitalBusan, South KoreaEnrolling by invitation
  • Keimyung University Dongsan HospitalDaegu, South KoreaEnrolling by invitation
  • Daejeon Endo Internal Medicine ClinicDaejeon, South KoreaEnrolling by invitation
  • Konyang University HospitalDaejeon, South KoreaEnrolling by invitation
  • National Health Insurance Corporation Ilsan HospitalGoyang-si, South KoreaEnrolling by invitation
  • Chung-Ang University Gwangmyeong HospitalGwangmyeong-si, Gyeonggi-do, South KoreaEnrolling by invitation
  • Seoul National University Bundang HospitalSeongnam-si, South KoreaEnrolling by invitation
  • CHA Bundang Medical CenterSeongnam-si, Gyeonggi-do, South KoreaEnrolling by invitation
  • Seoul Happiness Clinic of internal medicineSeongnam-si, Gyeonggi-do, South KoreaEnrolling by invitation
  • Chung ang University HospitalSeoul, South KoreaEnrolling by invitation
  • Ewha Womans University Seoul HospitalSeoul, South KoreaEnrolling by invitation
  • Korea University Guro HospitalSeoul, South KoreaEnrolling by invitation
  • Ajou University HospitalSuwon, South KoreaEnrolling by invitation
  • The Catholic University of Korea Uijeongbu St. Mary's HospitalUijeongbu-si, South KoreaEnrolling by invitation
  • Uijeongbu Eulji university HospitalUijeongbu-si, Gyeonggi-do, South KoreaEnrolling by invitation
  • Pusan National University Yangsan HospitalYangsan, South KoreaEnrolling by invitation
  • Yongin Severance HospitalYongin-si, South KoreaEnrolling by invitation

About the trial

What the trial wants to find out

This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.

The group in the trial

  • Once weekly Wegovy

    Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.

    Treatment: Semaglutide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea
Plain-language title
Weight Loss and Safety of Semaglutide in Korean Adults Living With ObesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
30 September 2026